Astellas Pharma's Veoza Recommended by UK's NICE for NHS Use in Treating Menopause-Related Hot Flushes
This NICE recommendation opens up a significant new market for Astellas' Veoza within the UK's public healthcare system.
Astellas Pharma's Veoza received a positive recommendation from the UK's NICE for use within the NHS, expanding market access for the menopause symptom treatment.
The UK's National Institute for Health and Care Excellence (NICE) has recommended Astellas Pharma's drug, Veoza, for use within the National Health Service (NHS). This recommendation is for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause. The decision makes Veoza an accessible option for women in the UK experiencing these symptoms, following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
This NICE recommendation opens up a significant new market for Astellas' Veoza within the UK's public healthcare system. It provides a non-hormonal treatment option for a large patient population, potentially capturing market share from existing hormonal therapies and establishing Veoza as a key treatment for menopause symptoms in the UK.
Where this signal fits in the broader landscape.
https://www.thepharmaletter.com/pfizer-news/ice-backs-astellas-veoza-for-nhs-use
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In